RHYGAZE
Live / Registered — Registered (as of 03 Mar 2026)
What this means for you
Registered since 03 Mar 2026. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79413712
- Registration number
- 8155620
- Mark type
- Stylized text
- Filed
- 08 Nov 2024
- Published for opposition
- 13 Jan 2026
- Registered
- 03 Mar 2026
- Attorney of record
- James R Menker
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and medical preparations, namely, ophthalmologic preparations; biological medical and pharmaceutical preparations for treating ophthalmologic conditions, ailments, diseases and disorders; Pharmaceutical and medical preparations for treating eye diseases; biological medical and pharmaceutical preparations for treating eye diseases; pharmaceutical and biological preparations for use in cell cultures for medical purposes, namely, nucleic acids, protein arrays, protein conjugates, synthetic peptides, attenuated viruses, viral vectors and viral constructions; biological tissue cultures for medical use; biological tissue cultures intended for medical use in the diagnosis, prevention and treatment of diseases, in particular eye diseases; biological tissue cultures intended for medical use in gene therapy treatments; pharmaceutical preparations for use in genetic-based therapies, namely, gene therapy preparations, gene-editing preparations, genome-editing preparations, and preparations incorporating CRISPR-based therapeutic agents for the treatment of eye diseases and other medical conditions; biological preparations comprising genetically modified cells, modified nucleic acids, viral and non-viral vectors for use in gene therapy and genome-editing medical treatments; all of the foregoing excluding preparations or other goods for the treatment of cancer and oncological diseases and disorders
- Class 042 — Scientific and technological services: Scientific and technological services, namely, research and design services relating to gene therapy, genetic-based therapies, genome-editing technologies, CRISPR technologies, molecular biology, biotechnology, pharmacy and medicine; quality control for others and authentication of data in the field of medical records using blockchain technology; design and development of computers and software; research and development services in the fields of molecular biology, biotechnology, pharmacy and medicine; research and development services in the fields of molecular biology, biotechnology, pharmacy and medicine, in particular in the field of eye diseases; research and development services in the field of medical diagnostics, prophylaxis and therapy, in particular gene therapy; research services, namely, scientific examination and research of compounds and components intended for therapeutic or diagnostic use, in particular intended for use in relation to eye diseases; research services in the field of gene therapy; research and development in the fields of genome editing, CRISPR-based technologies, and genetic-engineering tools for medical and therapeutic use; scientific research for developing protocols, for technical planning, and for providing advice in the fields of molecular biology, biotechnology and pharmacy, in particular intended for use in the field of ocular diseases and gene therapies
- Class 044 — Medical, beauty and agricultural services: Medical services; medical services, namely medical diagnosis through molecular biology, genetic engineering and biotechnology methods, in particular in the field of eye diseases; therapy services, in particular gene therapy for medical treatment purposes
Owner
- RhyGaze AG, Basel, CH
- RhyGaze AG, Basel, CH
- RhyGaze AG, Basel, CH
Prosecution history
- 10 Sept 2026 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 25 Aug 2026 — FINAL DISPOSITION NOTICE SENT TO IB
- 25 Aug 2026 — FINAL DISPOSITION PROCESSED
- 18 Jun 2026 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
- 03 Jun 2026 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 01 Jun 2026 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 31 May 2026 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 06 Apr 2026 — LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
- 03 Mar 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 03 Mar 2026 — REGISTERED-PRINCIPAL REGISTER
- 13 Jan 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 13 Jan 2026 — PUBLISHED FOR OPPOSITION
- 07 Jan 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 16 Dec 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 15 Dec 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED